trimipramine both increase QTc interval. Use Caution/Monitor. clozapine and trimipramine both increase sedation. Use Caution/Monitor.cobicistatMonitor Closely (3)cobicistat will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response cobicistat will increase the level or effect of trimipramine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat. cobicistat will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cocaine topicalMonitor Closely (1)trimipramine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.codeineMonitor Closely (1)codeine and trimipramine both increase sedation. Use Caution/Monitor.conjugated estrogensMinor (1)conjugated estrogens, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalMinor (1)conjugated estrogens, vaginal, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.crizotinibMonitor Closely (2)crizotinib and trimipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval. crizotinib increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemerMonitor Closely (1)crofelemer increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizineMonitor Closely (2)cyclizine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. cyclizine and trimipramine both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (2)cyclobenzaprine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. cyclobenzaprine and trimipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.cyclophosphamideMinor (1)cyclophosphamide will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyproheptadineMonitor Closely (1)cyproheptadine and trimipramine both increase sedation. Use Caution/Monitor.dabrafenibMonitor Closely (1)dabrafenib will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dacomitinibSerious - Use Alternative (1)dacomitinib will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. dantroleneMonitor Closely (1)dantrolene and trimipramine both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)trimipramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinMonitor Closely (1)darifenacin and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.darunavirMonitor Closely (1)darunavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibMonitor Closely (1)trimipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.debrisoquineMonitor Closely (1)trimipramine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.degarelixMonitor Closely (1)degarelix and trimipramine both increase QTc interval. Use Caution/Monitor.desfluraneMonitor Closely (2)desflurane and trimipramine both increase QTc interval. Use Caution/Monitor. desflurane and trimipramine both increase sedation. Use Caution/Monitor.Minor (1)desflurane, trimipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.desipramineMonitor Closely (2)desipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. desipramine and trimipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)desipramine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug. desipramine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.desvenlafaxineSerious - Use Alternative (1)trimipramine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.deutetrabenazineMonitor Closely (2)trimipramine and deutetrabenazine both increase sedation. Use Caution/Monitor. deutetrabenazine and trimipramine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and trimipramine both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (2)trimipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. trimipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.dexmedetomidineMonitor Closely (1)dexmedetomidine and trimipramine both increase sedation. Use Caution/Monitor.dexmethylphenidateMonitor Closely (1)trimipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)dexmethylphenidate increases effects of trimipramine by decreasing metabolism. Minor/Significance Unknown.dextroamphetamineMonitor Closely (3)trimipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor. trimipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely. trimipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.dextroamphetamine transdermalMonitor Closely (1)trimipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.dextromethorphanSerious - Use Alternative (1)trimipramine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.dextromoramideMonitor Closely (1)dextromoramide and trimipramine both increase sedation. Use Caution/Monitor.diamorphineMonitor Closely (1)diamorphine and trimipramine both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and trimipramine both increase sedation. Use Caution/Monitor.diazepam intranasalMonitor Closely (1)diazepam intranasal, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dicyclomineMonitor Closely (1)dicyclomine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diethylpropionMonitor Closely (1)trimipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.difelikefalinMonitor Closely (1)difelikefalin and trimipramine both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)difenoxin hcl and trimipramine both increase sedation. Use Caution/Monitor.dihydroergotamineMonitor Closely (1)trimipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalMonitor Closely (1)trimipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.diltiazemMonitor Closely (1)diltiazem will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinateMonitor Closely (1)dimenhydrinate and trimipramine both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (2)diphenhydramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. diphenhydramine and trimipramine both increase sedation. Use Caution/Monitor.diphenoxylate hclMonitor Closely (1)diphenoxylate hcl and trimipramine both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)dipipanone and trimipramine both increase sedation. Use Caution/Monitor.disopyramideContraindicated (1)trimipramine and disopyramide both increase QTc interval. Contraindicated.dobutamineMonitor Closely (1)trimipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.dofetilideMonitor Closely (1)dofetilide increases toxicity of trimipramine by QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (1)trimipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)dolasetron, trimipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.donepezilMonitor Closely (1)donepezil increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)donepezil and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.dopamineMonitor Closely (1)trimipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.dopexamineMonitor Closely (1)trimipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.doxepinMonitor Closely (2)doxepin and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. doxepin and trimipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)doxepin and trimipramine both increase QTc interval. Avoid or Use Alternate Drug. doxepin and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.doxylamineMonitor Closely (1)doxylamine and trimipramine both increase sedation. Use Caution/Monitor.dronedaroneSerious - Use Alternative (1)trimipramine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.droperidolMonitor Closely (1)droperidol and trimipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duloxetineSerious - Use Alternative (1)duloxetine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.echothiophate iodideMonitor Closely (1)echothiophate iodide increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzMonitor Closely (3)efavirenz will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. efavirenz will decrease the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. efavirenz and trimipramine both increase QTc interval. Use Caution/Monitor.elagolixMonitor Closely (2)elagolix will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates. elagolix decreases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eletriptanMonitor Closely (1)eletriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustatMonitor Closely (2)eliglustat increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect. eliglustat and trimipramine both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (2)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibMonitor Closely (1)encorafenib, trimipramine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)encorafenib and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.entrectinibMonitor Closely (1)entrectinib and trimipramine both increase QTc interval. Use Caution/Monitor.ephedrineMonitor Closely (2)trimipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor. trimipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.epinephrineMonitor Closely (2)trimipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor. trimipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)epinephrine and trimipramine both increase QTc interval.